Transplant outcome according to HLA class I or II mismatch
| Outcome . | Day +100* . | +1 year* . | +4 years* . | HR (95% CI)† . | P‡ . |
|---|---|---|---|---|---|
| HLA class I mismatched patients (n = 51) | |||||
| Acute 2-4 GVHD | 29 (17-42) | ||||
| Acute 3-4 GVHD | 4 (0-9) | ||||
| Chronic GVHD | 44 (30-58) | 63 (49-77) | |||
| NRM | 2 (0-6) | 16 (6-27) | 19 (8-30) | ||
| Relapse/progression | 20 (9-31) | 28 (15-41) | |||
| Progression-free survival | 64 (50-77) | 53 (38-68) | |||
| Overall survival | 71 (59-84) | 61 (47-76) | |||
| Bacterial infection | 63 (49-76) | 65 (51-79) | |||
| Fungal infection | 8 (0-15) | 15 (5-25) | |||
| CMV reactivation§ | 43 (27-59) | 43 (27-59) | |||
| Other viral infection | 40 (26-54) | 45 (30-59) | |||
| Patients with HLA class II mismatches (n = 25) | |||||
| Grade 2-4 acute GVHD | 48 (28-68) | 1.97 (0.92-4.21) | .09 | ||
| Acute 3-4 GVHD | 0 (–) | 0.0 (undefined) | .20 | ||
| Chronic GVHD | 24 (7-41) | 46 (26-66) | 0.57 (0.29-1.15) | .11 | |
| NRM | 8 (0-19) | 12 (0-25) | 16 (2-31) | 0.73 (0.23-2.30) | .58 |
| Relapse/progression | 24 (7-41) | 33 (14-52) | 1.33 (0.55-3.20) | .54 | |
| Progression-free survival | 64 (45-83) | 51 (30-71) | 1.05 (0.52-2.09) | .90 | |
| Overall survival | 72 (54-90) | 62 (43-82) | 0.83 (0.38-1.81) | .64 | |
| Bacterial infection | 67 (47-87) | 67 (47-87) | 0.93 (0.50-1.74) | .82 | |
| Fungal infection | 8 (0-19) | 18 (2-33) | 1.24 (0.36-4.23) | .74 | |
| CMV reactivation§ | 40 (15-65) | 40 (15-65) | 0.96 (0.38-2.43) | .93 | |
| Other viral infection | 50 (30-70) | 50 (30-70) | 1.60 (0.82-3.14) | .18 |
| Outcome . | Day +100* . | +1 year* . | +4 years* . | HR (95% CI)† . | P‡ . |
|---|---|---|---|---|---|
| HLA class I mismatched patients (n = 51) | |||||
| Acute 2-4 GVHD | 29 (17-42) | ||||
| Acute 3-4 GVHD | 4 (0-9) | ||||
| Chronic GVHD | 44 (30-58) | 63 (49-77) | |||
| NRM | 2 (0-6) | 16 (6-27) | 19 (8-30) | ||
| Relapse/progression | 20 (9-31) | 28 (15-41) | |||
| Progression-free survival | 64 (50-77) | 53 (38-68) | |||
| Overall survival | 71 (59-84) | 61 (47-76) | |||
| Bacterial infection | 63 (49-76) | 65 (51-79) | |||
| Fungal infection | 8 (0-15) | 15 (5-25) | |||
| CMV reactivation§ | 43 (27-59) | 43 (27-59) | |||
| Other viral infection | 40 (26-54) | 45 (30-59) | |||
| Patients with HLA class II mismatches (n = 25) | |||||
| Grade 2-4 acute GVHD | 48 (28-68) | 1.97 (0.92-4.21) | .09 | ||
| Acute 3-4 GVHD | 0 (–) | 0.0 (undefined) | .20 | ||
| Chronic GVHD | 24 (7-41) | 46 (26-66) | 0.57 (0.29-1.15) | .11 | |
| NRM | 8 (0-19) | 12 (0-25) | 16 (2-31) | 0.73 (0.23-2.30) | .58 |
| Relapse/progression | 24 (7-41) | 33 (14-52) | 1.33 (0.55-3.20) | .54 | |
| Progression-free survival | 64 (45-83) | 51 (30-71) | 1.05 (0.52-2.09) | .90 | |
| Overall survival | 72 (54-90) | 62 (43-82) | 0.83 (0.38-1.81) | .64 | |
| Bacterial infection | 67 (47-87) | 67 (47-87) | 0.93 (0.50-1.74) | .82 | |
| Fungal infection | 8 (0-19) | 18 (2-33) | 1.24 (0.36-4.23) | .74 | |
| CMV reactivation§ | 40 (15-65) | 40 (15-65) | 0.96 (0.38-2.43) | .93 | |
| Other viral infection | 50 (30-70) | 50 (30-70) | 1.60 (0.82-3.14) | .18 |
CMV, cytomegalovirus.
Data are survival or cumulative incidence percentage (95% CI).
Hazard ratio (HR) is for class II vs class I mismatch.
P values reflect comparisons between HLA class I and class II mismatched patients based on high-resolution genotyping over the entire period of follow-up.
Excluding seronegative pairs.